Is GLP-1 the Same as Semaglutide — or Are They Different Things?

Step 1, Understand what GLP-1 actually is

Glucagon-like peptide-1 is released from cells in your small intestine within minutes of eating. It does several things at once: it signals the pancreas to release insulin in proportion to blood-glucose levels, it slows the rate at which the stomach empties, and it reaches the brain's appetite centres to reduce hunger. The effect is short-lived; natural GLP-1 breaks down in the bloodstream within a couple of minutes.

That brief lifespan is exactly why researchers spent years building medicines that activate the same receptor but stay active far longer. Semaglutide has a half-life of roughly one week, which is why it can be taken once weekly. The receptor it binds is the GLP-1 receptor, which is why semaglutide belongs to the class called GLP-1 receptor agonists. Other drugs in the same class include liraglutide, though liraglutide and semaglutide differ considerably in structure, dosing frequency and trial outcomes.

So when someone asks whether GLP-1 is the same as semaglutide, the clearest answer is: GLP-1 is the hormone; semaglutide is a drug that mimics it. One is biology, the other is pharmacology.

Step 2, Understand where semaglutide sits within the GLP-1 class

Semaglutide is a single-receptor agonist. It activates the GLP-1 receptor only. Tirzepatide, by contrast, activates both the GLP-1 and GIP receptors simultaneously, making it a dual agonist and a structurally different class of medicine, even though it also interacts with the GLP-1 receptor. If you have seen the question whether GLP-1 medicines are the same as semaglutide phrased more broadly, the answer expands: semaglutide is one member of the GLP-1 receptor agonist family, not the whole family.

In the UK, the licensed GLP-1 receptor agonists for weight management are semaglutide (Wegovy, injection and tablets) and, through its GLP-1 component, tirzepatide (Mounjaro). Liraglutide (Saxenda) is also licensed for weight management but works through the same single-receptor mechanism as semaglutide, at a lower potency per trial data. The semaglutide overview on our site covers the clinical profile in more depth.

One quick habit worth building: if you ever see a product described only as a "GLP-1" without a specific medicine name, check the medicine's brand, generic name and licensed indication on the NHS medicines page for semaglutide or equivalent. Takes under a minute and removes a lot of confusion.

Step 3, Know which semaglutide products are licensed for weight management in the UK

Semaglutide comes in several commercial forms, and they are not all licensed for the same thing. Wegovy (the injection, 0.25 mg up to 2.4 mg or the newer 7.2 mg dose) is licensed specifically for weight management in adults. Ozempic is also semaglutide, but its UK licence covers type 2 diabetes, it should not be used for weight loss, and prescribing it off-label for that purpose is not appropriate. Rybelsus is oral semaglutide, but its 3 mg, 7 mg and 14 mg tablets are licensed for diabetes, not weight management.

The newest addition is Wegovy tablets, approved by the MHRA on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. The tablet schedule runs from 1.5 mg up to a 25 mg maintenance dose. If the weekly injection is one of the things you have been researching, the Wegovy page covers both formats. For those wondering whether the injection and the tablet are truly equivalent, this comparison walks through what the evidence currently says.

On cost: private Wegovy prices vary by dose and provider, and understanding what a quoted price does and does not include matters before you commit. Wegovy cost in the UK breaks down the market context honestly. The broader question of which weight-loss treatment might suit your situation is best explored through a clinical assessment rather than a product page, our weight-loss treatment overview is a useful starting point.

Step 4, Why the distinction matters when you are choosing treatment

Knowing that semaglutide is a GLP-1 receptor agonist does not on its own tell you whether it is the right medicine for you. Licensed eligibility for Wegovy requires a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. A prescriber also reviews your full health picture: other medicines you take, relevant conditions and whether your goals align with what the medicine is designed to do.

The NICE recommendation for semaglutide (TA875) sets its own criteria for NHS access, including use within a specialist weight management service for a maximum of two years. Private access through a regulated pharmacy does not require a referral, but the clinical assessment is just as real. At nume, a GPhC-registered prescriber reviews every consultation personally, your answers go to a clinician, not a filtering algorithm. That clinical review is why semaglutide, and GLP-1 medicines generally, require a prescription rather than an over-the-counter purchase.

If you are weighing semaglutide against tirzepatide, this page on Wegovy and GLP-1 mechanisms goes further on the pharmacology side, and this related piece covers the overlap question from a different angle. The question of which suits you is one for a prescriber rather than a search engine, if you are ready to explore that, start your free consultation and a clinician will review your case the same day.